

# Collecting Cancer Data: Hematopoietic and Lymphoid Neoplasms

NAACCR 2015-2016 Webinar Series

Presented by:

Angela Martin [amartin@naaccr.org](mailto:amartin@naaccr.org)

Jim Hofferkamp [jhofferkamp@naaccr.org](mailto:jhofferkamp@naaccr.org)



## ●●● Q&A

- Please submit all questions concerning webinar content through the Q&A panel.
- Reminder:
  - If you have participants watching this webinar at your site, please collect their names and emails.
  - We will be distributing a Q&A document in about one week. This document will fully answer questions asked during the webinar and will contain any corrections that we may discover after the webinar.

## ●●● Fabulous Prizes



3

NAACCR  
National Cancer Registry  
Association

## ●●● Agenda

- Hematopoietic Database and Manual
- Questions/Answers from Ask SEER Registrar
- Quiz
- Staging
- Quiz
- Case Scenarios

4

NAACCR  
National Cancer Registry  
Association

5



Overview

Hematopoietic & Lymphoid Neoplasms

### ●●● Ambiguous Terminology

- Use to screen all reports except cytology and tumor markers
- Can use equivalent terms “favored” rather than “favor(s)” but not substitute synonyms “equal” for “comparable with”. Do not substitute “likely” for “most likely”
- Accept reportable term used even if another part of medical record uses a term not on the reportable list
- Followback is recommended
- If biopsy or physician’s statement confirms non-reportable do not report
- Do not report ambiguous cytology

6

## ●●● Ambiguous Terminology

<b>Apparently</b>	<b>Most likely</b>
<b>Appears</b>	<b>Presumed</b>
<b>Comparable with</b>	<b>Probable</b>
<b>Compatible with</b>	<b>Suspect(ed)</b>
<b>Consistent with</b>	<b>Suspicious (for)</b>
<b>Favor(s)</b>	<b>Typical (of)</b>
<b>Malignant appearing</b>	

Hematopoietic and Lymphoid Neoplasm Coding Manual pg23



## ●●● Diagnostic Confirmation

- No priority hierarchy
- Use Code 1 ONLY when tissue, bone marrow, or blood used to diagnose specific histology
- Originally confirmed by histology (Code 1) and then immunophenotyping, genetic testing or JAK2 confirms more specific with no evidence of transformation – Code 3
- Hematopoietic and Lymphoid Neoplasm Coding Manual pg 13



## ●●● Diagnostic Confirmation

### Microscopically Confirmed

- Code 1 – Positive histology
  - Bone marrow specimens
  - Peripheral blood smear (9590/3-9992/3)
    - Flow cytometry
  - Leukemia only (9800/3 – 9948/3) – CBC, WBC
  - Microscopically confirmed AND
    - Immunophenotyping, genetic testing or JAK2 not done OR done but negative
- Code 2 – Positive cytology (rarely used)

9



## ●●● Diagnostic Confirmation

### Microscopically Confirmed

- Code 3 – Positive histology PLUS
  - Positive immunophenotyping AND/OR
  - Positive genetic studies
- Code 4 – Positive microscopic confirmation, method not specified
  - Rarely used;

10



## ●●● Diagnostic Confirmation

### Not Microscopically Confirmed

- Code 5 – Positive Lab test/marker study; rarely used
- Code 6 – Direct visualization w/o microscopic confirmation
- Code 7 – Radiology and other imaging techniques w/o microscopic confirmation
- Code 8 – Clinical diagnosis only

### Confirmation Unknown

- Code 9 – Unknown whether or not microscopically confirmed, DCO

11



## ●●● Transformations

- A chronic neoplasm is a neoplasm that can transform TO an acute/more severe neoplasm
  - CLL/SLL (9823/3)
  - Diffuse large B-cell lymphoma (9680/3)
- An acute neoplasm is a neoplasm that may have transformed FROM a chronic neoplasm
  - Plasma Cell myeloma (9732/3)
  - Solitary plasmacytoma of bone (9731/3)

12



13



The Database

Hematopoietic & Lymphoid Neoplasms

### ●●● Five steps to using the Hematopoietic Database

- Identify the working histology code(s)
- Determine the number of primaries
- Verify or revise the working histology code(s)
- Determine primary site
- Determine the grade

14

### ●●● Example

A patient is diagnosed at your facility in 2016 with acute myeloid leukemia. Looking in your registry database you see that the patient was diagnosed and treated for refractory anemia with ring sideroblasts in 2010.

15



### ●●● Step 1: Identify the working histology code(s)

- Refractory anemia with ring sideroblasts
  - 9982/3
- Acute myeloid leukemia
  - 9861/3

16





## ●●● Step 2: Determine the number of primaries

- Rule M10: Abstract as multiple primaries when a neoplasm is originally diagnosed as a chronic neoplasm AND there is a second diagnosis of an acute neoplasm more than 21 days after the chronic diagnosis.
  - Note 1: Use the Heme DB multiple Primaries Calculator to determine the number of primaries when a transformation from a chronic to an acute neoplasm occurs

17



## ●●● Step 3: Verify or revise the working histology code(s)

- 2010 – 9982/3
- 2016 – 9861/3

18



●●● **Step 4: Determine primary site**

- 2010 - C421
- 2016 - C421

19



●●● **Step 5: Determine the grade**

- 2010 – Grade 9
- 2016 – Grade 9

20



21

Questions/Answers

from Ask SEER Registrar

Hematopoietic &amp; Lymphoid Neoplasms

### ●●● Question 1

- Please see below - should this be coded to CLL/SLL 9823/3 or non reportable

#### FINAL INTERPRETATION

Monoclonal B-cell lymphocytosis ("high count" per WHO 2016) showing the immunophenotype of CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA. The neoplastic cells are expressing monotypic lambda immunoglobulin light chains.

22

### ●●● Question 1

- Yes, you can use this diagnosis to abstract this case as 9823/3 for CLL/SLL.

23



### ●●● Question 2

- Path reports states: Deep cervical lymph node (excision): Follicular lymphoma in situ. See note.

Note: This diagnosis is rendered in consultation with Dr. Ellen McPhail of the Mayo Clinic in Rochester, MN (order# V7554683). Dr. McPhail states the following in her comment: The findings support the diagnosis of follicular lymphoma in situ.

Comment: Follicular lymphoma in situ is of uncertain malignant potential and often will not progress to overt follicular lymphoma. Clinicopathologic correlation is strongly recommended."

24



## ●●● Question 2

- Per the Case Reportability Instructions, #3:  
Note: Do not report in situ lesions.

25



## ●●● Question 3

- Patient transformed from 9945/3 to 9895/3, Can we say there is now no evidence of disease for the 9945/3 since it has transformed into 9895/3?

26



### ●●● Question 3

- If there is no documentation that shows evidence that the disease is still present, then yes, you can say there is no evidence of disease.

27



### ●●● Question 4

- What diagnostic confirmation code should be used for the following case 2015 lymphoma case:

Patient was diagnosed and treated for T lymphoblastic lymphoma of mediastinum based on pericardial fluid cytology. Immunophenotyping on fluid confirmed the subtype. Bone marrow exam was negative, and the patient did not have a tissue biopsy.

28





#### Question 4

- Since there is immunophenotyping that confirmed the diagnosis, use code 3.

29



#### Question 5

- How would you code "Anaplastic large cell lymphoma, ALK neg". The Hematopoietic rules database only shows a code for ALK pos.

30



### ●●● Question 5

- Assign histology 9702/3, Peripheral T-cell lymphoma, NOS . One of the alternate names is "Anaplastic large cell lymphoma, ALk neg."

31



### ●●● Question 6

- Patient diagnosed with chronic myelomonocytic leukemia March 2015 and then in June 2015 diagnosed with myeloid sarcoma found in skin, is this a new primary?  
Looking at rule M3, says chronic myeloid leukemia is the exception to this rule. Although morphology 9945/3 is not one of the listed morphologies for chronic in rule M3.
- Then using the MP Calculator, says New primary. NOTE: AML 9861/3 and Myeloid sarcoma 9930/3 also states New primary when using the calculator, but AML, NOS 9860/3 and 9930/3 says Same primary?

32





### ●●● Question 6

- Chronic myelomonocytic leukemia is grouped with the myelodysplastic/myelodysplasia syndromes. It is not covered in Rule M3. M15 would apply, which is to abstract the second primary of myeloid sarcoma, 9930/3.
- In terms of the multiple primary calculator, only use this when instructed by the multiple primary rules. Using it at any other time could result in the wrong number of primaries.

33



### ●●● Question 7

- DLBCL (9680/3) of the stomach Nov 2015 and due to abnormality on PET imaging was found to have plasmablastic lymphoma (9735/3) of the tonsil early December 2015.
- The physician documents Stage IV DLBCL of the stomach and tonsil. However, after review of the Heme rules and database, it appears this is actually 2 separate primaries, correct?

34



## ●●● Question 7

- As a reminder, physician's don't use the same rules that we do. Sometimes the way physician's count primaries will be different than how we collect them. You are to follow the rules as defined in the Heme Manual and Database
- You are correct, this is 2 primaries. Rule M15 applies, which states to use the multiple primaries calculator. The MPC shows that the plasmablastic lymphoma (9735/3) is a second primary.

35



36

Quiz 1

Hematopoietic &amp; Lymphoid Neoplasms



## 1 Localized

- Stage I
  - Involvement of a single lymph node region
- Stage IE
  - Localized involvement of a single extralymphatic organ/site
  - Multifocal involvement of one extralymphatic organ/site
- Stage IS
  - Localized involvement of spleen only



## 5 Regional, NOS

- Stage II
  - Involvement of two or more lymph node regions on the SAME side of the diaphragm
- Stage IIE
  - Direct extension to adjacent organs or tissues
  - Localized involvement of a single extralymphatic organ/site WITH involvement of its regional lymph node(s) or WITH involvement of other lymph node(s) on the SAME side of the diaphragm
- Stage IIS
  - Involvement of spleen PLUS lymph node(s) BELOW the diaphragm
- Stage IIES
  - Involvement of spleen PLUS localized involvement of a single extralymphatic organ/site BELOW the diaphragm WITH/WITHOUT involvement of lymph node(s) BELOW the diaphragm



## 7 Distant

- Stage III
  - Involvement of lymph node regions on BOTH sides of the diaphragm
- Stage IIIE
  - Involvement of an extralymphatic organ or site PLUS involvement of lymph node(s) on the OPPOSITE side of the diaphragm
- Stage IIIS
  - Involvement of the spleen PLUS involvement of lymph node(s) ABOVE the diaphragm
- Stage IIIES
  - Involvement of the spleen PLUS involvement of lymph node region(s) ABOVE the diaphragm PLUS involvement of a single extralymphatic organ/site on either side of the diaphragm
  - Involvement of the spleen PLUS a single extralymphatic organ/site ABOVE the diaphragm WITH OR WITHOUT involvement of lymph node(s)



## 7 Distant (cont.)

- Stage IV
  - Disseminated involvement of ONE OR MORE extralymphatic organ(s)/site(s)
  - (Multifocal) involvement of MORE THAN ONE extralymphatic organ/site
- Metastases
  - Bone marrow



AJCC & Summary Stage

Staging

Hodgkin and Non-Hodgkin Lymphoma

Lymphoma

### • T, N, and M Values

- Values

- T, N, and M values are not defined in the AJCC Manual for Hodgkin and Non-Hodgkin lymphoma.
- When values are not defined for the T, N, M or Stage Group data items in the AJCC manual for a site/histology combination, NPCR, CoC, and SEER have all agreed that a value of 88 should be entered.

### ••• T, N, and M Values

- Hodgkin or Non-Hodgkin Lymphoma with an unknown stage
  - T, N, and M are defaulted to 88
  - Stage group is 99

Data Item	Value
Clinical T	88
Clinical N	88
Clinical M	88
Clinical Stage	99
Pathologic T	88
Pathologic N	88
Pathologic M	88
Pathologic Stage	99



### ••• Pop Quiz

- Acute myelogenous leukemia...what is the stage group?

Data Item	Value
Clinical T	88
Clinical N	88
Clinical M	88
Clinical Stage	88
Pathologic T	88
Pathologic N	88
Pathologic M	88
Pathologic Stage	88




## Rules for Classification

- Clinical
  - Biopsy
    - Excisional biopsy if lymph nodes
  - Imaging
    - X-Ray
    - CT
    - FDG-PET
  - Bone Marrow
- Pathologic
  - Staging laparotomy is required
  - Essentially abandoned as a stage classification



## Stage I


- Involvement of a single lymph node region
- Involvement of a single *extranodal* site
- Involvement of a single *extralymphatic* site





Stage II

- Involvement of two or more lymph node regions on the same side of the diaphragm



Bilateral Lymph Node Regions

- Cervical, supraclavicular, occipital, preauricular
- Infraclavicular
- Hilar
- Axillary
- Pelvic
- Inguinal/femoral
- If both sides are involved, count as two lymph node regions




Image source: SEER Training Website NAACCR

### ●●● Axial Lymph Node Regions

- Axial
  - Mediastinal
  - ~~Hilar~~
  - Para-aortic
  - Mesenteric
- Each counts as 1 lymph node region
- Extranodal lymphatic sites each count as 1 region
  - Spleen, thymus, tonsils, Peyer’s patches




Image source: SEER Training Website



### ●●● Other Lymph Node Regions

- Internal mammary \*
- Epitrochlear \*\*
- Popliteal \*\*
- Occipital \*
- Submental \*
- Preauricular \*\*

\*Count as one lymph node region

\*\*Count as two lymph node regions if both sides are involved




Image source: SEER Training Website



## Defining Lymph Node Involvement

- Clinical enlargement (without other explanation such as infection)
- Pathologic diagnosis
- Imaging: nodes larger than 1.5 cm



## Pop Quiz


- A patient presented with a palpable right cervical lymph node that did not respond to standard treatment. A biopsy confirmed lymphoma. Additional work-up showed enlarged left and right cervical lymph nodes. No additional disease was identified.
- What is the stage?

Data Item	Value
Clinical T	88
Clinical N	88
Clinical M	88
Clinical Stage	2A
Pathologic T	88
Pathologic N	88
Pathologic M	88
Pathologic Stage	99



## Stage IIE

- Involvement of one extralymphatic site with regional lymph node involvement
- Direct extension from a lymph node to an extralymphatic site
- All involvement is on one side of the diaphragm



## Extranodal Lymphatic Sites

- Spleen (C42.2)
- Thymus Gland (C37.9)
- Lingual Tonsil (C02.4)
- Palatine Tonsil (C09.9)
- Waldeyers's ring (C14.2)
- Peyer's patches (C17.2)
- Lymphoid nodules of the appendix (C18.1)

*These sites are **NOT** designated by an "E" in the stage group*

### Common Extralymphatic Sites

- Stomach
- Small Intestine
- Uterus
- Bone
- Brain
- Breast
- Large Intestine
- Others

*These sites **are** designated by an “E” in the stage group*



### Spleen Involvement (“S” Suffix)

- Unequivocal palpable splenomegaly
- Equivocal palpable splenomegaly with radiologic confirmation
- Radiologic enlargement AND multiple focal defects (not cystic or vascular)



### Clinical Stage Descriptor

Code	Label	Description
0	None	There are no prefix or suffix descriptors that would be used for this case
1	<b>E- Extranodal, lymphomas only</b>	<b>A lymphoma case involving an extranodal site</b>
2	<b>S- Spleen, lymphomas only</b>	<b>A lymphoma case involving the spleen</b>
3	M-Multiple primary tumors in a single site	This is one primary with multiple tumors in the organ of origin at the time of diagnosis
5	<b>E&amp;S- Extranodal and spleen, lymphomas only</b>	<b>A lymphoma case with involvement of both an extranodal site and the spleen</b>
9	Unknown, not stated in patient record	A prefix or suffix would describe this stage, but it is not know which would be correct



### Pop Quiz

- A patient is found to have a primary parotid lymphoma. Staging work-up shows the lymphoma is confined to the parotid gland. The entire parotid gland was removed and pathology confirms the disease was confined to the parotid gland. No further treatment was done.

Data Item	Value
Clinical T	88
Clinical N	88
Clinical M	88
Clinical Stage	1A
Pathologic T	88
Pathologic N	88
Pathologic M	88
Pathologic Stage	99
Clin Stage Descriptor	1



### Pop Quiz


- A patient is found to have a large mediastinal mass. The mass extends into the left lung. No additional abnormalities were identified. A biopsy of the mass confirms lymphoma.

Data Item	Value
Clinical T	88
Clinical N	88
Clinical M	88
Clinical Stage	2A
Pathologic T	88
Pathologic N	88
Pathologic M	88
Pathologic Stage	99
Clin Stage Descriptor	1



### Stage III


- Involvement of lymph nodes on both sides of the diaphragm






### Stage III E

- Involvement on both sides of the diaphragm
  - Involvement of one extralymphatic site with regional lymph node involvement
  - Direct extension from a lymph node to an extralymphatic site
  - Involvement of the spleen (S)
  - Involvement by the spleen and an extranodal site (E,S)



### Stage IV


- Diffuse or Disseminated involvement of more than one extralymphatic organ
- Disease in distant sites






### Determining Stage IV Disease

- Site of origin
  - Stomach, colon, brain, uterus
    - Most likely extralymphatic
  - Bone, lung
    - Most likely Stage IV
  - Liver, bone marrow, cerebrospinal fluid, pleura
    - **ALWAYS** stage IV



### Summary



## SSF 2

- Note 1: Each stage should be classified as either A or B according to the absence or presence of defined constitutional symptoms, such as:
  - 1. Fevers: Unexplained fever with temperature above 38 degrees C;
  - 2. Night sweats: Drenching sweats that require change of bedclothes;
  - 3. Weight loss: Unexplained weight loss of more than 10% of the usual body weight in the 6 months prior to diagnosis.
- Note 2: Pruritus alone does not qualify for B classification, nor does alcohol intolerance, fatigue, or a short, febrile illness associated with suspected infections.
- Note 3: Use code 000 if the History and Physical, progress notes, or consultations make no mention of B symptoms.
- **Every stage group should have an A or B**
- **If B symptoms are coded in SSF 2, then stage group must have a B**



## Mets at DX BBDLLO

- Distant mets can be coded in these data items for lymphoma!
  - Do not use code 8 (not applicable) for lymphoma primaries
  - Code bone marrow involvement for any site except for primary site bone marrow as code 1 in Mets at Dx-Other
  - Code a positive peripheral blood smear as code 1 in Mets at Dx-Other
  - Carcinomatosis may be coded as 2 in Mets at Dx Other

Data Items
Mets at Dx Bone
Mets at Dx Brain
Mets at Dx Distant Lymph Node
Mets at Dx Liver
Mets at Dx Lung
Mets at Dx Other



Questions?

Quiz 2 and Case Scenarios

69

### Coming Up...

- Collecting Cancer Data: Lung
  - 12/1/2016
- AJCC Staging
  - 1/12/2017

## ●●● Fabulous Prizes



71



## ●●● CE Certificate Quiz/Survey

- Phrase
- Link
  - <http://www.surveygizmo.com/s3/3155288/Heme-2016>





Jim Hofferkamp [jhofferkamp@naaccr.org](mailto:jhofferkamp@naaccr.org)  
Angela Martin [amartin@naaccr.org](mailto:amartin@naaccr.org)  
Recinda Sherman [rsherman@naaccr.org](mailto:rsherman@naaccr.org)

